



King Saud University

Saudi Pharmaceutical Journal

www.ksu.edu.sa
www.sciencedirect.com



ORIGINAL ARTICLE

Antiproliferative effects of aspirin and diclofenac against the growth of cancer and fibroblast cells: In vitro comparative study



Marwan S.M. Al-Nimer ^{a,*}, Huda G. Hameed ^{b,1}, Majid M. Mahmood ^{c,2}

^a Department of Pharmacology, College of Medicine, Al-Mustansiriya University, Baghdad, Iraq

^b Department of Clinical Pharmacy, Al-Yarmouk Teaching Hospital, Ministry of Health, Baghdad, Iraq

^c Department of Biology, College of Science, Al-Mustansiriya University, Baghdad, Iraq

Received 24 October 2014; accepted 1 January 2015

Available online 10 January 2015

KEYWORDS

Cancer cells;
In vitro;
Anticancer;
Diclofenac;
Aspirin

Abstract Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the growth of several cancer cell lines. The aim of this study is to compare the cytotoxic effect of aspirin with diclofenac on the growth of HeLa cell, mammary cell carcinoma, rhabdomyosarcoma and fibroblast cell lines in the culture media. The cells are cultured in RPMI-1640 culture media supplemented with 5% fetal calf serum and antibiotics. Aspirin (5 mg/well) and diclofenac (0.625 mg/well) significantly inhibit the growth of HeLa, rhabdomyosarcoma and fibroblast cells. The cytotoxic effect of aspirin against rhabdomyosarcoma is significantly ($p < 0.001$) higher than that of diclofenac with a potency approximated 2.6. It concludes that aspirin and diclofenac inhibit the growth of fibroblast and cancer cell by inhibiting the up-regulation of cyclooxygenases enzymes in cancer cells. Aspirin is more effective than diclofenac against the growth of rhabdomyosarcoma cell line.

© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Regular uses of non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the risk of cancers of colon, breast, lung and ovary (Cuzick et al., 2009; Rothwell et al., 2012; Wernli et al., 2008).

Experimental studies demonstrated that diclofenac inhibits the growth of tumor xenografts (Mayorek et al., 2010; Moody et al., 2010) as well as the proliferation of cancer cell in a concentration dependent manner (Smirnova et al., 2012). Diclofenac inhibits the growth of melanoma cell by increasing the cellular level of reactive oxygen species due to inhibition

* Corresponding author at: Department of Pharmacology, College of Medicine, Al-Mustansiriya University, P.O. 14132, Baghdad, Iraq. Mobile: +964 7902600291.

E-mail addresses: alnimermarwan@gmail.com (M.S.M. Al-Nimer), ehab_ayad2000@yahoo.com (H.G. Hameed), majidmahmood93@yahoo.com (M.M. Mahmood).

¹ Mobile: +964 7901143585.

² Mobile: +964 7901392945.

Peer review under responsibility of King Saud University.



Production and hosting by Elsevier

the activity of superoxide dismutase enzyme in mitochondria (Albano et al., 2013).

Aspirin induced apoptosis and inhibits the proliferation of HeLa cells in a concentration dependent manner by a mechanism related to the inhibition of the proto-oncogene (ErbB2) downstream cell survival signaling pathways (Xiang et al., 2010).

Aspirin interferes with the pathways of the proliferation rhabdomyosarcoma cells by inhibiting the induction of the matrix metalloproteinase enzyme activity (Ito et al., 2004). Recently, Siddesha et al. (2014) demonstrated that aspirin inhibits the migration of mouse cardiac fibroblast by attenuating the level of interleukin-18, an interleukin involved in different pathways that ultimately lead to reduce the migration of fibroblast and reducing fibrosis. In one study, aspirin reduced the breast cell line KM22 adhesion to human umbilical vein endothelial cell while diclofenac failed to demonstrate that effect (Bischofs et al., 2012).

The rationale for doing this study is that aspirin or diclofenac exerts a specific inhibitory action against the proliferation of cells that links to its selectivity against cyclooxygenases enzymes. This study aimed to compare the inhibitory effect aspirin and diclofenac (non-selective cyclooxygenases enzyme inhibitors) on the growth of three different cancer cell line and fibroblast.

2. Materials and methods

This study was conducted in the Department of Pharmacology in the College of Medicine incorporation with National Center of Cancer Research at Al-Mustansiriya University, Baghdad, Iraq during 2014. The study was approved by the Institutional Scientific Committee at the College of Medicine.

2.1. Cell Culture treatment and viability

HeLa, human rhabdomyosarcoma, mammary (AMN3) adenocarcinoma and primary rat embryo fibroblast cell lines (provided from The National Center of Cancer Research in Baghdad, Iraq) were maintained in RPMI-1640 media with 5% fetal calf serum. All cultures were maintained in medium supplemented with 0.5% ampicillin and 0.5% streptomycin in 5% CO₂ at 37 °C. Several trials of cell reactivation are done in order to obtain a monolayer cells in a specific falcon (volume 25 ml) which can be adjusted under the microscope to look for the presence of monolayer cells. Once the growth of monolayer cells has been formed, the old growth media discarded, washed with phosphate buffer saline (PBS) buffer once, add 0.5–1 ml Trypsin-versin solution, then add 10 ml sterile growth media (supplemented with 5% fetal calf serum). Then the dispersed cells transferred into a sterile microplate. A total volume of 200 µl cells suspension is transferred into the wells of the microplate, incubated at 37 °C for 24 h to achieve a monolayer cells growth. The cells were plated at 1×10^5 cells per well in 200 µl of complete culture medium containing aspirin (5 mg) or diclofenac (0.625 mg) and incubated at 37 °C for 24 h. The concentration of aspirin that used in this study amounted 8 times of that of diclofenac in attempt to mimic the maximum tolerated therapeutic doses of these drugs.

The sterilization of the herbal tea achieved by mechanical filtration (using 0.2 µm millipore filter device) prior to the

addition. On the next day (i.e. after 24 h), the viability of cells was determined by the MTT assay. A 30 µl of prepared tetrazolium dye (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazoliumbromide (5 mg/ml in phosphate buffer solution) was added to each well in a dark room (to avoid oxidation of the dye), and incubated for 2 h at 37.5 °C in the incubator. Then after, whole wells contents are discarded, 100 µl dimethyl sulfoxide added, shake the microtitre plate for 15 min by using horizontal shaker before recording the absorbance of each well at 540 nm by ELISA reader.

2.2. Statistical analysis

The results are expressed as number, percent and whenever possible as mean ± SD. The data are analyzed using Student's *t* test (unpaired, two tailed) and the difference between percentages test taking the probability of ≤0.05 is the lowest limit of significance.

3. Results

Aspirin significantly ($p < 0.001$) inhibits the growth of fibroblast cell ($53.7\% \pm 6.3\%$) compared with un-treated cells ($100 \pm 23\%$) (Fig. 1). A significant ($p < 0.001$) inhibitory effect of aspirin against the growth of HeLa cell line is observed ($17.0 \pm 3.3\%$) compared with untreated cells ($100 \pm 18.5\%$) (Fig. 1). A non-significant ($p > 0.05$) cytotoxic effects of aspirin is observed ($103.1 \pm 28.7\%$) against rhabdomyosarcoma cell line compared with un-treated cell line ($100.0 \pm 18.5\%$) (Fig. 1). The growth of rhabdomyosarcoma cell line is significantly ($p < 0.001$) inhibited with aspirin ($26.1 \pm 10.6\%$) compared with un-treated cell line ($100 \pm 26.1\%$) (Fig. 1). As with aspirin, diclofenac has no significant effect against the growth of AMN3 mammary cell line compared with un-treated cell line ($118.5 \pm 25.9\%$ versus $100 \pm 18.5\%$, respectively). The significant effects of diclofenac against fibroblast, HeLa and rhabdomyosarcoma cell lines are inferior to that observed with aspirin (Fig. 2). The percents of fibroblast, HeLa and rhabdomyosarcoma cell lines growth decreased into $74.9 \pm 10.8\%$, $21.2 \pm 5.5\%$ and $67.0 \pm 25.3\%$ respectively. The cytotoxic effect of aspirin against rhabdomyosarcoma is significantly ($p < 0.001$) higher




Figure 1 Effect of aspirin on the growth of different cell lines. The results are expressed as mean ± SD of each treatment ($n = 8$), * $p < 0.001$.




Figure 2 Effect of diclofenac on the growth of different cell lines. The results are expressed as mean \pm SD of each treatment ($n = 8$), * $p < 0.05$, ** $p < 0.02$, *** $p < 0.001$.

than diclofenac sodium with a potency approximated 2.6 ($26.1 \pm 10.6\%$ versus $67.0 \pm 25.3\%$).

4. Discussion

Aspirin and diclofenac significantly inhibit the growth of HeLa, rhabdomyosarcoma and the fibroblast cell line. The inhibitory effects of aspirin are higher than diclofenac sodium that reached significant against rhabdomyosarcoma. This study shows that the inhibitory effect of aspirin on the growth of HeLa cells is in agreement with other study that showed aspirin potentiated the effect of the reversing (antitumor compound) at a concentration of 10 mmol/L (Qin et al., 2013) which is lower than the concentration of this study. Lee et al. (2008) suggested that the anti-proliferative effect of aspirin is due to the induction of the antitumor calpain via activation of the caspase-3. Wang et al. (2002) reported an inhibition of HeLa cell growth by diclofenac sodium in a concentration higher than that reported in this study. Therefore, the cytotoxic effect of diclofenac may approximate the effect of aspirin if equal-concentrations are used. The significant differences between diclofenac and aspirin against the growth of rhabdomyosarcoma may be related to the cyclooxygenase expression as well as to the level of the matrix metalloproteinase enzymes of the cells (Ito et al., 2004; Dickens and Cripe, 2003).

Reed et al. (2011) reported that celecoxib, a cyclooxygenase-2 inhibitor, inhibits the formation of rhabdomyosarcoma colonies, and they linked this effect to the different mechanisms including inhibition of interleukin-6 induction and phosphorylation of STAT (Signal Transducer and Activator of Transcription) protein signaling. The cytotoxic inhibitory effects of aspirin and diclofenac are related to their effects on cyclooxygenases enzymes -1 and -2 in which they show up-regulation expression in fibroblast (Abdou et al., 2014). Recently, a new pharmaceutical formula termed closed packed vesicle-diclofenac is developed. This pharmaceutical preparation can attack the fibroblast cells and deposited in these cells (Manca et al., 2013). Therefore, the difference between aspirin and diclofenac against the fibroblast cell growth may be related to the concentration of the drug that deposited in fibroblast cells. The results of NSAIDs on the mammary cell growth do not agree the previous reports that showed aspirin induced breast cancer apoptosis in presence of over-expression

of Bcl-2 gene (Choi et al., 2013; Hu et al., 2012). Therefore, NSAIDs inhibit the growth of breast cell cancer in specific experimental models, otherwise, their cytotoxic effect is missed.

5. Conclusion

We conclude that aspirin and diclofenac inhibit the growth of fibroblast and cancer cell by inhibiting the up-regulation of cyclooxygenases enzymes in cancer cells.

Acknowledgements

This work supported by the College of Medicine, Al-Mustansiriya University. The authors expressed their thanks to the members of the National Center of Cancer Research for their cooperation and provided us unlimited supports.

References

- Abdou, A.G., Maraee, A.H., Saif, H.F., 2014. Immunohistochemical evaluation of COX-1 and COX-2 expression in keloid and hypertrophic scar. *Am. J. Dermatopathol.* 36, 311–317.
- Albano, F., Arcucci, A., Granato, G., et al., 2013. Markers of mitochondrial dysfunction during the diclofenac-induced apoptosis in melanoma cell lines. *Biochimie* 95, 934–945.
- Bischofs, E., Lubs, D., Fritzsche, F., et al., 2012. In vitro blockade of adhesion of breast cancer cells to endothelial cells using anti-inflammatory drugs. *Anticancer. Res.* 32, 767–771.
- Choi, B.H., Chakraborty, G., Baek, K., et al., 2013. Aspirin-induced Bcl-2 translocation and its phosphorylation in the nucleus trigger apoptosis in breast cancer cells. *Exp. Mol. Med.* 45, e47.
- Cuzick, J., Otto, F., Baron, J.A., et al., 2009. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. *Lancet. Oncol.* 10, 501–507.
- Dickens, D.S., Cripe, T.P., 2003. Effect of combined cyclooxygenase-2 and matrix metalloproteinase inhibition on human sarcoma xenografts. *J. Pediatr. Hematol. Oncol.* 25, 709–714.
- Hu, L.X., Du, Y.Y., Zhang, Y., et al., 2012. Synergistic effects of exemestane and aspirin on MCF-7 human breast cancer cells. *Asian. Pac. J. Cancer. Prev.* 13, 5903–5908.
- Ito, H., Duxbury, M., Benoit, E., et al., 2004. Fibronectin-induced COX-2 mediates MMP-2 expression and invasiveness of rhabdomyosarcoma. *Biochem. Biophys. Res. Commun.* 318, 594–600.
- Lee, S.K., Park, M.S., Nam, M.J., 2008. Aspirin has antitumor effects via expression of calpain gene in cervical cancer cells. *J. Oncol.* 2008, 285374.
- Manca, M.L., Manconi, M., Falchi, A.M., et al., 2013. Close-packed vesicles for diclofenac skin delivery and fibroblast targeting. *Colloids. Surf. B. Biointerfaces* 111C, 609–617.
- Mayorek, N., Naftali-Shani, N., Grunewald, M., 2010. Diclofenac inhibits tumor growth in a murine model of pancreatic cancer by modulation of VEGF levels and arginase activity. *PLoS ONE* 5, e12715.
- Moody, T.W., Switzer, C., Santana-Flores, W., et al., 2010. Dithiol-ethione modified valproate and diclofenac increase E-cadherin expression and decrease proliferation of non-small cell lung cancer cells. *Lung. Cancer.* 68, 154–160.
- Qin, H.X., Yang, J., Cui, H.K., et al., 2013. Synergistic antitumor activity of reversine combined with aspirin in cervical carcinoma in vitro and in vivo. *Cytotechnology* 65, 643–653.
- Reed, S., Li, H., Li, C., et al., 2011. Celecoxib inhibits STAT3 phosphorylation and suppresses cell migration and colony forming ability in rhabdomyosarcoma cells. *Biochem. Biophys. Res. Commun.* 407, 450–455.

- Rothwell, P.M., Price, J.F., Fowkes, F.G., et al, 2012. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. *Lancet* 379, 1602–1612.
- Siddesha, J.M., Valente, A.J., Sakamuri, S.S., et al, 2014. Acetylsalicylic acid inhibits IL-18-induced cardiac fibroblast migration through the induction of RECK. *J. Cell. Physiol.* 229, 845–855.
- Smirnova, A.V., Lazebnik, L.B., Trubitsina, I.E., et al, 2012. Antiproliferative activity of diclofenac at tumor cell cultures. *Eksp. Klin. Gastroenterol.* 5, 66–69.
- Wang, K., Shindoh, H., Inoue, T., et al, 2002. Advantages of in vitro cytotoxicity testing by using primary rat hepatocytes in comparison with established cell lines. *J. Toxicol. Sci.* 27, 229–237.
- Wernli, K.J., Newcomb, P.A., Hampton, J.M., et al, 2008. Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity. *Br. J. Cancer.* 98, 1781–1783.
- Xiang, S., Sun, Z., He, Q., et al, 2010. Aspirin inhibits ErbB2 to induce apoptosis in cervical cancer cells. *Med. Oncol.* 27, 379–387.